Informations générales (source: ClinicalTrials.gov)
Clinical and Genetic Analyzes of Age-related Macular Degeneration (COLDMLA)
Observational
Centre Hospitalier Intercommunal Creteil (Voir sur ClinicalTrials)
novembre 2005
novembre 2024
29 juin 2024
The purpose of this collection is to search for susceptibility genes for age-related
macular degeneration (AMD) alone or in combination with environmental factors and to look
for genes that modulate the AMD phenotype (particularly the response to treatment).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Eric SOUIED | 29/03/2024 01:26:58 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHNO DES QUINZE-VINGTS PARIS | José-Alain Sahel, MD PhD | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Pellegrin - 33000 - Bordeaux - France | Jean-François Korobelnik, MD, PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHI Créteil - 94000 - Créteil - France | Eric Soueid | Contact (sur clinicalTrials) | |||
| Hôpital général de Dijon - 21033 - Dijon - France | Catherine Creuzot-Garcher, MD PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age> 55 years
- Diagnosis of exudative or atrophic AMD in at least one eye
- Patient informed of the objectives of the study and having freely signed the
informed consent letter
- Patient affiliated to a social security scheme
- Age> 55 years
- Diagnosis of exudative or atrophic AMD in at least one eye
- Patient informed of the objectives of the study and having freely signed the
informed consent letter
- Patient affiliated to a social security scheme
- Other retinal or choroidal lesion in the studied eye
- History of severe systemic disease that could potentially hinder patient adherence
to the study protocol: mental disorder, cancer, recent stroke or heart failure less
than 3 months old.
- Known allergy to fluorescein, indocyanine green, iodine or ranibizumab